Physician profile
Amy E Wright
NPI 1740274737
$2,910.15
in general payments reported to CMS, 2019-2025
30 companies · $628 in 2025
The $628 reported for 2025 was more than what 85% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $591 · 2020: $253 · 2021: $205 · 2022: $516 · 2023: $431 · 2024: $286 · 2025: $628.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,246 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,246.29 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $460.21 | 2022-2025 | Veozah |
| Mayne Pharma Commercial LLC | $344.25 | 2021-2025 | |
| Abbvie INC. | $214.87 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $206.58 | 2019-2023 | Gardasil 9 |
| Hologic Sales and Service, LLC | $177.98 | 2022-2025 | Myosure Tissue Removal Device, Aptima, Thinprep 2000 Processor |
| Organon LLC | $158.71 | 2021-2025 | Nexplanon, Nuvaring |
| Pfizer INC. | $154.67 | 2019-2025 | |
| Therapeuticsmd, INC. | $147.41 | 2019-2022 | |
| Novo Nordisk INC | $118.73 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Agile Therapeutics, INC. | $108.98 | 2021-2023 | Twirla |
| Exeltis, USA INC. | $83.09 | 2019-2023 | Slynd |
| Amag Pharmaceuticals, INC. | $68.76 | 2019 | |
| Exact Sciences Corporation | $67.52 | 2024-2025 | Cologuard Collection Kit |
| Sumitomo Pharma America, INC. | $66.18 | 2024-2025 | Myfembree |
| Ascend Therapeutics US, LLC | $61.70 | 2021-2023 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Duchesnay USA Incorporated | $61.47 | 2019 | |
| Convatec INC. | $58.21 | 2022-2023 | |
| Biogen, INC. | $49.21 | 2025 | Zurzuvae |
| Mylan Pharmaceuticals INC. | $45.26 | 2019-2020 | |
| Channel Medsystems, INC. | $36.52 | 2025 | |
| Daiichi Sankyo INC. | $34.48 | 2020 | |
| Vertical Pharmaceuticals, LLC | $33.90 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $33.19 | 2019-2023 | |
| Allergan, INC. | $28.29 | 2019 | |
| Avation Medical, INC. | $21.35 | 2025 | Vivally System |
| Millicent US INC | $17.36 | 2025 | Femlyv |
| Shield Therapeutics INC | $17.18 | 2023 | Accrufer |
| Lilly USA, LLC | $16.19 | 2025 | Zepbound |
| Coopersurgical, INC. | $13.30 | 2019 | |
| Abbott Laboratories | $4.60 | 2024 | Diamondback Coronary |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Wright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.